Beneficial effects of valsartan on target lesion revascularization after percutaneous coronary interventions with bare-metal stents

Circulation Journal

Volumn 75, Issue 7, 2011, Pages 1641-1648

  Okada, Takenori ^a   Yamamoto, Hideya ^a   Okimoto, Tomokazu ^a,b   Otsuka, Masaya ^a,b   Ishibashi, Ken ^a   Dohi, Yoshihiro ^c   Fujii, Takashi ^a,c,d   Tadehara, Futoshi ^e   Kurisu, Satoshi ^a   Hayashi, Yasuhiko ^b   Kihara, Yasuki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b TSUCHIYA GENERAL HOSPITAL   (Japan)

^c Kure Kyosai Hospital   (Japan)

^d JA Hiroshima General Hospital at Jigozen   (Japan)

^e MAZDA HOSPITAL   (Japan)

Author keywords

Percutaneous coronary intervention; Restenosis; Revascularization; Stents

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; PLACEBO; VALSARTAN;

ADD ON THERAPY; ADULT; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOTENSION; JAPAN; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE CARE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; METALS; MIDDLE AGED; PROSPECTIVE STUDIES; STENTS; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 79959761752     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1064     Document Type: Article

References (36)

1. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-495.
2. Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Salter LF, Popma JJ, et al. Small stent size and intimal hyperplasia contribute to restenosis: A volumetric intravascular ultrasound analysis. J Am Coll Cardiol 1995; 26: 720-724.
3. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
4. Stone GW, Ellis SG, Cox DA, Hermiller J, O'shaughnessy C, Mann JT, et al; TAXUS-IV Investigators. A polymer-based, paclitaxeleluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
5. Cheng CI, Lee FY, Chang JP, Hsueh SK, Hsieh YK, Fang CY, et al. Long-term outcomes of intervention for unprotecetd left main coronary artery stenosis: Coronary stenting vs coronary artery bypass grafting. Circ J 2009; 73: 705-712.
6. Park KW, Kang SH, Chung WY, Lee HY, Park JS, Kang HJ, et al. 'Real world' comparison of drug-eluting stents vs bare metal stents in the treatment of unselected patients with acute ST-segment elevation myocardial infarction. Circ J 2010; 74: 1111-1120.
7. Tamekiyo H, Hayashi Y, Toyofuku M, Ueda H, Tadamichi S, Okimoto T, et al. Clinical outcomes of sirolimus-eluting stenting after rotational atherectomy. Circ J 2009; 73: 2042-2049.
8. Takahashi S, Kaneda H, Tanaka S, Miyashita Y, Shiono T, Taketani Y, et al. Late angiographic stent thrombosis after sirolimus-eluting stent implantation. Circ J 2007; 71: 226-228.
9. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, et al; BASKET investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation baremetal stent in a real-world setting: Randomised Basal stent Kosten Effektivitäts trial (BASKET). Lancet 2005; 366: 921-929.
10. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
11. Otsuka M, Yamamoto H, Okimoto T, Dohi Y, Mito S, Gomyo Y, et al. Long-term effects of quinapril with high affinity for tissue angiotensin-converting enzyme after coronary intervention in Japanese. Am Heart J 2004; 147: 662-668.
12. Peters S, Götting B, Trümmel M, Rust H, Brattström X. Valsartan for prevention of restenosis after stenting of type B2/C lesions: The Val-PREST trial. J Invasive Cardiol 2001; 13: 93-97.
13. Yoshida O, Hirayama H, Nanasato M, Watanabe T, Murohara T. The angiotensin II receptor blocker candesartan cilexetil reduced neointimal proliferation after coronary stent implantation: A prospective randomized study under intravascular ultrasound guidance. Am Heart J 2005; 149: e1-e6.
14. Wakayama T, Ogawa H, Iida H, Takaki A, Iwami T, Mochizuki M, et al. Effects of candesartan and probucol on restenosis after coronary stenting: Results of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) Trial. Circ J 2003; 67: 519-524.
15. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50.
16. Levy AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
17. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: Implications for patient selection: Multivessel Angioplasty Prognosis Study Group. Circulation 1990; 82: 1193-1202.
18. van der Zwet PM, Reiber JH. A new approach for the quantification of complex lesion morphology: The gradient field transform; basic principles and validation results. J Am Coll Cardiol 1994; 24: 216-224.
19. Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, et al. Angiotensin II receptor blocker-based vs non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203-1212.
20. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439.
21. Bestenhorn HP, Neumann FJ, Büttner HJ, Betz P, Strürzenhofecker P, von Hondenberg E, et al. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: The randomized, double-blind, placebo-controlled, multicenter verapamil slow-release for prevention of cardiovascular events after angioplasty (VESPA) trial. J Am Coll Cardiol 2004; 43: 2160-2165.
22. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: Macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98: 224-233.
23. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, et al. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992; 19: 267-274.
24. Nozawa Y, Matsuura N, Miyake H, Yamada S, Kimura R. Effects of TH-142177 on angiotensin II-induced proliferation, migration and intracellular signaling in vascular smooth muscle cells and on neointimal thickening after balloon injury. Life Sci 1999; 64: 2061-2070.
25. Peters S, Götting B, Trümmel M, Rust H, Brattström A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: The Val PREST trial. J Invasive Cardiol 2001; 13: 93-97.
26. Peters S, Trümmel M, Meyners W, Koehler B, Westermann K. Trümmel Valsartan versus ACE inhibition after bare metal stent implantation: Results of the VALVLACE trial. Int J Cardiol 2005; 98: 331-335.
27. Radke PW, Figulla HR, Drexler H, Klues HG, Mügge A, Silber S, et al; AACHEN Trial Investigators. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. Am Heart J 2006; 152: 761.e1-e6.
28. Iwata A, Miura S, Imaizumi S, Kiya Y, Nishikawa H, Zhang B, et al. Do valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J 2007; 71: 32-38.
29. Peters S. Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions. Am J Cardiovasc Drugs 2008; 8: 83-87.
30. Munakata M, Nagasaki A, Nunokawa T, Sakuma T, Kato H, Yoshinaga K, et al. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens 2004; 17: 1050-1055.
31. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 2116-2123.
32. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al; Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
33. Cutlip DE, Chauhan MS, Baim DS, Ho K, Popma JJ, Bachinsky W, et al. Clinical restenosis after coronay stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40: 2082-2089.
34. Ribichini F, Wijns W, Ferreo V, Matullo G, Camilla T, Feola M, et al. Effect of angiotensin-converting enzyme inhibition on restenosis after coronary stenting. Am J Cardiol 2003; 91: 154-158.
35. Jørgensen E, Kelbæk H, Helqvist S, Jensen GV, Saunamäki K, Kastrup J, et al. Predictors of coronary in-stent restenosis: Importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2001; 38: 1434-1439.
36. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al; TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005; 294: 1215-1223.